TrialJAMA dermatology2021

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.

Sophie Glatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.